|Application ||WB, E|
|Other Accession||Q9D1C1, Q4R9D1, Q32PA5|
|Predicted||Bovine, Monkey, Mouse|
|Calculated MW||19652 Da|
|Antigen Region||10-39 aa|
|Other Names||Ubiquitin-conjugating enzyme E2 C, UbcH10, Ubiquitin carrier protein C, Ubiquitin-protein ligase C, UBE2C, UBCH10|
|Target/Specificity||This UBE2C antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 10-39 amino acids from the N-terminal region of human UBE2C.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||UBE2C Antibody (N-term G25) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys- 11'- and 'Lys-48'-linked polyubiquitination. Acts as an essential factor of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated ubiquitin ligase that controls progression through mitosis. Acts by initiating 'Lys-11'-linked polyubiquitin chains on APC/C substrates, leading to the degradation of APC/C substrates by the proteasome and promoting mitotic exit.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. UBE2C is a member of the E2 ubiquitin-conjugating enzyme family. This enzyme is required for the destruction of mitotic cyclins and for cell cycle progression.
Okamoto, Y., et al., Cancer Res. 63(14):4167-4173 (2003).
Lin, Y., et al., J. Biol. Chem. 277(24):21913-21921 (2002).
Townsley, F.M., et al., Proc. Natl. Acad. Sci. U.S.A. 94(6):2362-2367 (1997).
If you have any additional inquiries please email technical services at email@example.com.